Marco Ballarini

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignees: Dac S.r.l., Cogenia Srl, Congenia Slr. Active years: 2010-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marco Ballarini. Retrieved from https://idiyas.com/inventor/marco-ballarini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 7.6

ph-index = 2

Forward Citations = 8(Granted Patents)

Company Filing History:

Years Active: 2010-2014

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8669261 - Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition (2014-03-11),

2. 8470831 - Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition (2013-06-25),

3. 8242175 - Class of histone deacetylase inhibitors (2012-08-14),

4. 8058273 - Histone deacetylases inhibitors (2011-11-15),

5. 7803800 - Histone deacetylases inhibitors (2010-09-28),

Title: Marco Ballarini: Innovator in Mitochondrial Therapeutics

Introduction

Marco Ballarini is a prominent inventor based in Milan, Italy. He has made significant contributions to the field of therapeutic agents, particularly those targeting mitochondrial functions. With a total of five patents to his name, Ballarini's work focuses on innovative solutions for diseases associated with mitochondrial permeability transition.

Latest Patents

Among his latest patents are the "Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition." These derivatives serve as therapeutic agents aimed at preventing and treating conditions linked to the mitochondrial permeability transition pore (MPTP). The patents detail compounds that are effective against diseases characterized by ischemia/reperfusion and oxidative or degenerative tissue damage. The structural formula of these compounds is defined in the specifications, which also cover their preparation and pharmaceutical compositions.

Career Highlights

Throughout his career, Marco Ballarini has worked with notable companies such as Dac S.r.l. and Congenia S.r.l. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Some of his notable coworkers include Saverio Minucci and Antonello Mai. Their collaborative efforts have further advanced the research and development of mitochondrial therapeutics.

Conclusion

Marco Ballarini stands out as a key figure in the field of mitochondrial therapeutics, with a focus on innovative acrylomido derivatives. His contributions through patents and collaborations highlight his commitment to advancing medical science.

Profile summary based on public USPTO records.